Skip to main content

Expression of HIF-1A/VEGF/ING-4 Axis in Pulmonary Sarcoidosis

  • Chapter
  • First Online:
Noncommunicable Diseases

Abstract

Angiogenesis/angiostasis regulated by hypoxia inducible factor-1A (HIF-1A)/vascular endothelial growth factor (VEGF)/inhibitor of growth protein 4 (ING-4) axis may be crucial for the course and outcome of sarcoidosis. Overexpression of angiogenic factors (activation of VEGF through HIF-1A) may predispose to chronic course and lung fibrosis, whereas immunoangiostasis (related to an overexpression of inhibitory ING-4) may be involved in granuloma formation in early sarcoid inflammation, or sustained or recurrent formation of granulomas. In this work we investigated gene expression of HIF-1A, VEGF and ING-4 in bronchoalveolar fluid (BALF) cells and in peripheral blood (PB) lymphocytes of sarcoidosis patients (n = 94), to better understand mechanisms of the disease and to search for its biomarkers. The relative gene expression level (RQ value) was analyzed by qPCR. The results were evaluated according to the presence of lung parenchymal involvement (radiological stage I vs. II–IV), acute vs. insidious onset, lung function tests, calcium metabolism parameters, percentage of lymphocytes (BALL %) and BAL CD4+/CD8+ in BALF, age, and gender. In BALF cells, the ING-4 and VEGF RQ values were increased, while HIF-1A expression was decreased. In PB lymphocytes all studied genes were overexpressed. Higher expression of HIF-1A in PB lymphocytes of patients with abnormal spirometry, and in BALF cells of patients with lung volume restriction was found. VEGF gene expression in BALF cells was also higher in patients with abnormal spirometry. These findings were in line with previous data on the role of HIF-1A/VEGF/ING-4 axis in the pathogenesis of sarcoidosis. Up-regulated HIF-1A and VEGF genes are linked to acknowledged negative prognostics.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • American Thoracic Society: European Respiratory Society: World Association of Sarcoidosis and Other Granulomatous Disorders (1999) Statement on sarcoidosis. Am J Respir Crit Care Med 160:736–755

    Google Scholar 

  • Antoniou KM, Tzouvelekis A, Alexandrakis MG, Sfiridaki K, Tsiligianni I, Rachiotis G, Tzanakis N, Bouros D, Milic-Emili J, Siafakas NM (2006) Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest 130:982–988

    Article  PubMed  Google Scholar 

  • Antoniou KM, Soufla G, Proklou A, Margaritopoulos G, Choulaki C, Lymbouridou R, Samara KD, Spandidos DA, Siafakas NM (2009) Different activity of the biological axis VEGF-Flt-1 (fms-like tyrosine kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: a bronchoalveolar lavage study. Clin Dev Immunol 537929. doi:10.1155/2009/537929

    Google Scholar 

  • Baughman RP, Nagai S, Balter M, Costabel U, Drent M, du Bois R, Grutters JC, Judson MA, Lambiri I, Lower EE, Muller-Quernheim J, Prasse A, Rizzato G, Rottoli P, Spagnolo P, Teirstein A (2011) Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis 28:56–64

    CAS  PubMed  Google Scholar 

  • Chciałowski A, Chorostowska-Wynimko J, Fal A, Pawłowicz R, Domagała-Kulawik J (2011) Recommendation of the Polish Respiratory Society for bronchoalveolar lavage (BAL) sampling, processing and analysis methods. Pneumonol Alergol Pol 79(2):75–89 (Article in Polish)

    Google Scholar 

  • Cui A, Anhenn O, Theegarten D, Ohshimo S, Bonella F, Sixt SU, Peters J, Sarria R, Guzman J, Costabel U (2010) Angiogenic and angiostatic chemokines in idiopathic pulmonary fibrosis and granulomatous lung disease. Respiration 80:372–378

    Article  CAS  PubMed  Google Scholar 

  • Déry MA, Michaud MD, Richard DE (2005) Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37:535–540

    Article  PubMed  Google Scholar 

  • Guérillon C, Bigot N, Pedeux R (2014) The ING tumor suppressor genes: status in human tumors. Cancer Lett 345:1–16

    Article  PubMed  Google Scholar 

  • Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP (1999) ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 16:149–173

    CAS  PubMed  Google Scholar 

  • Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Engl J Med 357:2153–2165

    Article  CAS  PubMed  Google Scholar 

  • Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, Chapman HA (2006) Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A 103:13180–13185

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lazarus A (2009) Sarcoidosis: epidemiology, etiology, pathogenesis, and genetics. Dis Mon 55:649–660

    Article  PubMed  Google Scholar 

  • Piotrowski WJ, Kiszałkiewicz J, Pastuszak-Lewandoska D, Antczak A, Górski P, Migdalska-Sęk M, Górski W, Czarnecka KH, Nawrot E, Domańska D, Brzeziańska-Lasota E (2014a) TGF-β and SMADs mRNA expression levels in pulmonary sarcoidosis. Adv Exp Med Biol. doi:10.1007/5584_2014_106

    Google Scholar 

  • Piotrowski WJ, Młynarski W, Fendler W, Wyka K, Marczak J, Górski P, Antczak A (2014b) Associations between chemokine receptor cxcr3 ligands in bronchoalveolar lavage fluid and radiological pattern, clinical course and prognosis in sarcoidosis. Pol Arch Med Wewn 124:395–402

    PubMed  Google Scholar 

  • Sekiya M, Ohwada A, Miura K, Takahashi S, Fukuchi Y (2003) Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis. Lung 181:259–265

    Article  CAS  PubMed  Google Scholar 

  • Shimoda LA, Semenza GL (2011) HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med 183:152–156

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Stenmark KR, Fagan KA, Frid MG (2006) Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99:675–691

    Article  CAS  PubMed  Google Scholar 

  • Thomas KW, Hunninghake GW (2003) Sarcoidosis. JAMA 289:3300–3303

    Article  PubMed  Google Scholar 

  • Tolnay E, Kuhnen C, Voss B, Wiethege T, Muller KM (1998) Expression and localization of vascular endothelial growth factor and its receptor flt in pulmonary sarcoidosis. Virchows Arch 432:61–65

    Article  CAS  PubMed  Google Scholar 

  • Tzouvelekis A, Ntolios P, Karameris A, Koutsopoulos A, Boglou P, Koulelidis A, Archontogeorgis K, Zacharis G, Drakopanagiotakis F, Steiropoulos P, Anevlavis S, Polychronopoulos V, Mikroulis D, Bouros D (2012) Expression of hypoxia-inducible factor (HIF)-1a-vascular endothelial growth factor (VEGF)-inhibitory growth factor (ING)-4- axis in sarcoidosis patients. BMC Res Notes 5:654

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Yamashita M, Mouri T, Niisato M, Kowada K, Kobayashi H, Chiba R, Satoh T, Sugai T, Sawai T, Takahashi T, Yamauchi K (2013) Heterogeneous characteristics of lymphatic microvasculatures associated with pulmonary sarcoid granulomas. Ann Am Thorac Soc 10:90–97

    Article  PubMed  Google Scholar 

  • Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, Semenza GL (1998) Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol 275:L818–L826

    CAS  PubMed  Google Scholar 

  • Zielonka TM, Demkow U, Radzikowska E, Bialas B, Filewska M, Życińska K, Obrowski MH, Kowalski J, Wardyn KA, Skopińska-Różewska E (2010) Angiogenic activity of sera from interstitial lung disease patients in relations to pulmonary function. Eur J Med Res 15(Suppl 2):229–234

    PubMed Central  PubMed  Google Scholar 

  • Ziora D, Dworniczak S, Niepsuj G, Niepsuj K, Jarosz W, Sielska-Sytek E, Ciekalska K, Oklek K (2000) Proangiogenic cytokines (bFGF and VEGF) in BALF from two different lung segments examined by high resolution computed tomography (HRCT) in patients with sarcoidosis. Pneumonol Alergol Pol 68:120–130

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was partially funded by the grant of the National Science Center (grant no. 2011/01/B/NZ5/04239).

Conflicts of Interest

The authors declare no conflicts of interest in relation to this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E. Brzeziańska-Lasota .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Piotrowski, W.J. et al. (2015). Expression of HIF-1A/VEGF/ING-4 Axis in Pulmonary Sarcoidosis. In: Pokorski, M. (eds) Noncommunicable Diseases. Advances in Experimental Medicine and Biology(), vol 866. Springer, Cham. https://doi.org/10.1007/5584_2015_144

Download citation

Publish with us

Policies and ethics